Altimmune just spent a single quarter transforming itself from a one-asset MASH developer into a multi-indication pemvidutide platform company with the global registrational Phase 3 trial now dosing patients, a positive Phase 2 readout in alcohol use disorder, and a completed enrollment in a third indication. On August 12, 2026, the company filed its second-quarter results covering the three months ended June 30, 2026, reporting a net loss of $22.8 million, or $0.12 per share, against $519 million in cash, cash equivalents, and investments. That balance sheet was rebuilt in the same quarter through an oversubscribed April 2026 public offering of common stock, pre-funded warrants, and stock warrants that delivered $225.0 million in gross proceeds and left the company funded into the second half of 2028 on the current burn trajectory.
The equity story, in our view, is no longer whether pemvidutide works - the IMPACT Phase 2b in MASH produced 24-week Breakthrough-Therapy-Designation-worthy data, and the July 2026 RECLAIM Phase 2 readout in AUD delivered a statistically significant reduction in heavy drinking days against placebo. The story is whether the global registrational program can be funded and executed to a 52-week MASH readout that management targets for 2029, while two parallel Phase 2 programs in alcohol use disorder and alcohol-associated liver disease consume capital. The market, in our reading, is pricing ALT like a single-program binary: 194.5 million shares outstanding, $519 million in cash, and the long-dated MASH catalyst anchoring nearly the entire equity value.
The single load-bearing risk is straightforward. Three concurrent Phase 2/3 programs, a Phase 3 that has just started enrolling, and only $519 million in cash against a $26.2 million quarterly operating-expense base that is rising as PERFORMA scales, means Altimmune likely needs to raise additional capital between now and the 2029 MASH readout. The dilution overhang is the most important variable in the equity over the next twelve months. The next falsifiable data point is the End-of-Phase 2 meeting with the FDA in AUD, which management says it plans to request following the July 2026 RECLAIM topline results.